Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $6.3800 (-4.06%) ($6.3800 - $6.3800) on Sat. Aug. 14, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.36% (three month average) | RSI | 57 | Latest Price | $6.3800(-4.06%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.8% a day on average for past five trading days. | Weekly Trend | HTBX advances 1.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting HTBX price | HTBX will decline at least -4.18% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.18% (StdDev 8.36%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
Resistance Level | $6.44 | 5 Day Moving Average | $6.57(-2.89%) | 10 Day Moving Average | $6.5(-1.85%) | 20 Day Moving Average | $6.44(-0.93%) | To recent high | -40.6% | To recent low | 7.2% | Market Cap | $N/A | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |